ATRA SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 16, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Atara Biotherapeutics Reports Q2 2026 Financial Results and Regulatory Progress for Tabelecleucel

Aug 12, 2026

8-K

Atara Biotherapeutics Announces Departure of Chief Accounting Officer and Appointment of Interim CFO

Jun 26, 2026

8-K

Atara Biotherapeutics Announces Board Appointment and Annual Meeting Results

Jun 12, 2026

8-K

Atara Biotherapeutics Reports Q1 2026 Financial Results and Progress on Tab-cel BLA Resubmission

May 12, 2026

8-K

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel (tab-cel) Following FDA Type A Meeting

May 7, 2026

8-K

Atara Biotherapeutics Receives Nasdaq Deficiency Notice Regarding Market Value Requirement

May 1, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* May 2026 ATM | Offering amount: $79,269,007 | Bank: TD Cowen

May 12, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 400,000

Mar 25, 2026

424B5

March 2026 ATM | Offering amount: $11,135,981 | Bank: TD Cowen

Mar 16, 2026

424B5

REGISTERED OFFERING

May 15, 2025

424B5

SHELF OFFERING | Shares amount: 758,900 | Share price: $8.25 | Warrants amount: 3,604,780 | Offering amount: $36,000,000.00

Sep 4, 2024

424B5

SHELF OFFERING | Shares amount: 27,272,727 | Share price: $0.55 | Warrants amount: 27,272,727 | Offering amount: $15,000,000.00

Jan 9, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8